The Management of Patients After High Risk Keratoplasty.
Wydanie 1/2021
str. 23 – 28
Autor: Joanna Major1, Bartosz Foroncewicz2, Krzysztof Mucha2,3, Jacek P. Szaflik1,4,5
1 Samodzielny Publiczny Kliniczny Szpital Okulistyczny w Warszawie
2 Klinika Immunologii, Transplantologii i Chorób Wewnętrznych Warszawskiego Uniwersytetu Medycznego
Kierownik: prof. dr hab. n. med. Leszek Pączek
3 Instytut Biochemii i Biofizyki Polskiej Akademii Nauk w Warszawie
Dyrektor: prof. dr hab. n. med. Jarosław Poznański
4 Katedra i Klinika Okulistyki Wydziału Lekarskiego Warszawskiego Uniwersytetu Medycznego
Kierownik: prof. dr hab. n. med. Jacek P. Szaflik
5 Centrum Mikrochirugii Oka Laser w Warszawie
Kierownik: prof. dr hab. n. med. Jerzy Szaflik
Summary:
Despite the presence of immune privilege of the eye, corneal graft rejection is the most common cause of loss of graft translucency. Many factors have been described to influence the rejection rate and loss of graft transparency. Among others deep corneal vascularization and multiple transplants. Undoubtedly, steroids are the most effective in prevention and treatment of rejection but their use is limited because of side effects occurrence. Hence the interest in nonsteroid immunosuppressants of which mycophenolate mofetil seems to have the best safety-to-efficacy ratio. However, still there are no guidelines for high-risk corneal recipients.